La Jolla Pharmaceutical (LJPC) Shares Down 0%
La Jolla Pharmaceutical (NASDAQ:LJPC)’s share price traded down 0% on Monday . The stock traded as low as $31.60 and last traded at $32.01. 1,440,000 shares traded hands during trading, an increase of 214% from the average session volume of 458,633 shares. The stock had previously closed at $32.01.
Several equities analysts have recently weighed in on the stock. BidaskClub upgraded shares of La Jolla Pharmaceutical from a “hold” rating to a “buy” rating in a report on Friday. Jefferies Group lowered shares of La Jolla Pharmaceutical from a “buy” rating to an “underperform” rating and dropped their price objective for the company from $40.00 to $29.00 in a report on Monday. ValuEngine upgraded shares of La Jolla Pharmaceutical from a “sell” rating to a “hold” rating in a report on Friday, February 2nd. Zacks Investment Research upgraded shares of La Jolla Pharmaceutical from a “hold” rating to a “buy” rating and set a $39.00 price objective on the stock in a report on Wednesday, November 1st. Finally, Chardan Capital upped their price objective on shares of La Jolla Pharmaceutical from $90.00 to $100.00 and gave the company a “buy” rating in a report on Thursday, January 25th. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and seven have given a buy rating to the company. La Jolla Pharmaceutical presently has an average rating of “Buy” and a consensus target price of $57.00.
The company has a market cap of $708.87, a PE ratio of -6.28 and a beta of 1.20.
Several large investors have recently bought and sold shares of LJPC. Janus Henderson Group PLC bought a new stake in shares of La Jolla Pharmaceutical during the second quarter worth about $25,191,000. State Street Corp increased its position in shares of La Jolla Pharmaceutical by 235.1% during the second quarter. State Street Corp now owns 1,180,368 shares of the biopharmaceutical company’s stock worth $35,140,000 after acquiring an additional 828,081 shares in the last quarter. Oak Ridge Investments LLC bought a new stake in shares of La Jolla Pharmaceutical during the third quarter worth about $14,642,000. Pictet Asset Management Ltd. bought a new stake in La Jolla Pharmaceutical in the 3rd quarter worth about $13,266,000. Finally, Candriam Luxembourg S.C.A. bought a new stake in La Jolla Pharmaceutical in the 3rd quarter worth about $6,295,000.
La Jolla Pharmaceutical Company Profile
La Jolla Pharmaceutical Company is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapies to improve outcomes in patients suffering from life-threatening diseases. LJPC-501 is its formulation of angiotensin II for the potential treatment of catecholamine-resistant hypotension (CRH).
Receive News & Ratings for La Jolla Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for La Jolla Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.